UTHR
United Therapeutics Corporation
545.00$
+0.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56.8% | 24.5% | 55.6% | 32.5% | 50.4% | 46.4% | 58.1% | 24.0% | 70.3% | 43.8% | 59.3% | 40.0% | 53.4% | |
| 2.2% | 2.2% | 2.2% | 2.6% | 2.6% | 2.7% | 2.5% | 2.6% | 2.7% | 2.9% | 2.9% | 3.1% | 2.9% | |
| 3.5% | 2.7% | 3.8% | 7.0% | 5.6% | 3.7% | 4.0% | 4.7% | 4.9% | 4.9% | 4.3% | 9.9% | 6.0% | |
| 7.5% | -14.9% | 5.9% | -15.2% | 1.7% | -0.6% | 9.8% | -25.4% | 20.3% | -18.2% | 1.6% | -15.8% | -3.0% | |
| 10.8% | 12.8% | 5.6% | 6.3% | 10.2% | 11.8% | 9.4% | 7.8% | 26.3% | 21.9% | 12.9% | 13.8% | 18.8% | |
| -51.4% | 6.8% | 108.5% | -11.2% | -15.3% | -16.7% | -20.7% | -37.6% | 17.6% | -28.8% | 95.2% | 11.2% | 23.6% | |
| – | 1.2% | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | -147.6% | -1.6% | -0.1% | 0.0% | -1.9% | -0.7% | -125.1% | 0.6% | -191.9% | -7.5% | -81.0% | |
| – | – | – | – | -13.4% | -13.6% | -12.6% | -25.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| 1.2% | -15.1% | -157.6% | -6.7% | -8.6% | -10.2% | -11.8% | -24.9% | -119.6% | 12.5% | -189.9% | 15.6% | -70.4% | |
| 6.6% | 16.3% | 6.5% | 14.6% | 26.5% | 19.5% | 25.5% | -38.4% | -31.6% | 27.5% | -61.8% | 93.1% | 6.7% | |
| 46.0% | 11.7% | 49.9% | 26.2% | 40.2% | 34.6% | 48.6% | 16.2% | 44.0% | 21.9% | 46.4% | 26.2% | 34.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.